title: European inter-institutional impact study of MammaPrint.
abstract: OBJECTIVE
  To measure the impact of MammaPrint on adjuvant treatment decisions and to analyze the agreement in treatment decisions between hospitals from 4 European countries for the same patient cohort.
  
  
  METHODS
  Breast cancer patients were prospectively enrolled and MammaPrint was assessed. Patients' clinical data without and then with MammaPrint results were sent to the different multidisciplinary teams and treatment advice was provided for each patient.
  
  
  RESULTS
  Using MammaPrint, chemotherapy treatment advice for ER+/HER2- breast cancer patients was changed in 37% of patients by the Dutch, 24% by the Belgian, 28% by the Italian and 35% by the Spanish teams. MammaPrint increased the inter-institutional agreement in treatment advice (chemotherapy or no chemotherapy) from 51% to 75%.
  
  
  CONCLUSIONS
  The results of this study indicate that MammaPrint impacts adjuvant chemotherapy recommendation. MammaPrint can decrease inter-institutional and inter-country variability in adjuvant treatment advice for breast cancer patients.
authors.affiliation: CHU Sart Tilman, Liège, Belgium. Electronic address: pino@cusumano.be.
authors.forename: P G
authors.initials: PG
authors.lastname: Cusumano
authors.affiliation: Istituti Ospitalieri di Cremona, Cremona, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Generali
authors.affiliation: Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Ciruelos
authors.affiliation: Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Manso
authors.affiliation: Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Ghanem
authors.affiliation: CHU Sart Tilman, Liège, Belgium.
authors.forename: E
authors.initials: E
authors.lastname: Lifrange
authors.affiliation: CHU Sart Tilman, Liège, Belgium.
authors.forename: G
authors.initials: G
authors.lastname: Jerusalem
authors.affiliation: Medisch Spectrum Twente, Enschede, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Klaase
authors.affiliation: Agendia NV, Amsterdam, The Netherlands.
authors.forename: F
authors.initials: F
authors.lastname: de Snoo
authors.affiliation: Agendia NV, Amsterdam, The Netherlands.
authors.forename: L
authors.initials: L
authors.lastname: Stork-Sloots
authors.affiliation: Agendia NV, Amsterdam, The Netherlands.
authors.forename: L
authors.initials: L
authors.lastname: Dekker-Vroling
authors.affiliation: Medisch Spectrum Twente, Enschede, The Netherlands; Saxenburgh Groep, Hardenberg, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Lutke Holzik
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D017024:Chemotherapy, Adjuvant / Q000379:methods; D005060:Europe; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D018579:Patient Selection; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D000068878:Trastuzumab; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000068878:Trastuzumab
keywords: Adjuvant chemotherapy; Breast cancer; Gene-expression profile; MammaPrint; Prognostic information; Treatment advice